Bristol Myers Squibb (NYSE: BMY) has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
The US pharma major says that the presentations reinforce its leadership in the cell therapy field.
Data presented included a long-term analyses reinforcing the durable efficacy and well-established safety profile of Breyanzi (lisocabtagene maraleucel) in large B-cell lymphoma (LBCL), follicular lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze